China Contract Research Organization (CRO) Industry Report, 2015-2018
  • July 2015
  • Hard Copy
  • USD $2,300
  • Pages:101
  • Single User License
    (PDF Unprintable)       
  • USD $2,100
  • Code: ZLC021
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,300
  • Hard Copy + Single User License
  • USD $2,500

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of 25.9%. With so many favorable policies, especially when a number of well-known proprietary drugs are about to expire, China’s CRO market size is expected to continue to grow by around 20% in the years ahead, to an estimated RMB 83.2 billion by 2018.

At present, some European and American CRO enterprises represented by Quintiles and Covance have penetrated the Chinese market by establishing branches or through acquisition and cooperation. These foreign giants, which occupy the majority of China’s CRO market share, are driving the industry to develop toward standardization.

There are more than 500 Chinese CRO enterprises, such as WuXi AppTec, Tigermed Consulting, Boji Medical Biotechnological, and HD Biosciences, which have a relatively large scale and develop very well. In 2014, WuXi AppTec represented a 9.69% market share while Tigermed Consulting and Boji Medical Biotechnological accounted for 1.47% and 0.34%, respectively.
As a leader in China’s CRO industry, WuXi AppTec posted revenue of RMB4.1266 billion (equivalent to USD674.3 million) in 2014, up 16.6% from a year earlier. In recent years, the company has seen rapid expansion by acquiring AppTec, ABGENT, Shanghai Medkey Med-Tech Development Co., and NextCODE Health.

Tigermed Consulting is a CRO company that specializes in the services related to clinical trials and clinical research. In 2014, the company recorded RMB624.6 million in revenue, up as high as 85.6%. In August 2012, the company completed its IPO, and then continuously strengthened its competitiveness through M&A and investment in subsidiaries. During 2013-2014, Tigermed Consulting founded Fantastic Bioimaging, Shanghai Tigermed Consulting Co., Hangzhou Talent MedCinsultant, and Tigermed-IntelliPV Ltd., and purchased BDM and Frontage Labs. In 2015, the company announced a proposed acquisition of Beiyi Renzhi (Beijing) Medical Technology Development Co. and DreamCIS Inc, a South Korean company.

Boji Medical Biotechnological, a comprehensive CRO company, was publicly traded on GEM of Shenzhen Stock Exchange in April 2015. As of the end of 2014, it had provided an accumulated more than 400 clinical research services and over 200 preclinical research services. In recent years, it has begun to focus on international expansion, successively undertaking the service projects of some overseas companies including Sweden’s Astrom Research International and South Korea’s Hyundai Pharmaceutical.

cro 英文_副本.png

China Contract Research Organization (CRO) Industry Report, 2015-2018 is mainly all about the following:
20120114.gifStatus quo, related policies, market size, competitive landscape, development trends, etc. of China’s CRO industry;
20120114.gifDevelopment environment of China’s CRO industry, including international environment, industry environment, and regional market;
20120114.gifOperation, R&D and investment, development in China, etc. of 5 global and 13 Chinese CRO companies;
20120114.gifDevelopment prediction of China’s CRO industry as well as operation of major enterprises.

1. Overview of Pharmaceutical Outsourcing
1.1 Definition
1.2 Classification
1.3 CRO

2. Overview of China CRO Market
2.1 Status Quo
2.2 Related Policies
2.3 Market Size
2.4 Competitive Landscape
2.5 Development Trends
2.5.1 Industrial Chain Improvement 
2.5.2 Internationalization of Qualification Certification Standard
2.5.3 Development Driven by Technical Innovation

3. Development Environment of China CRO Industry
3.1 International Environment
3.1.1 Development History
3.1.2 Development Status
3.1.3 Major Countries and Regions
3.2 Industry Environment
3.3 Regional Market
3.3.1 Beijing
3.3.2 Shanghai
3.3.3 Chengdu

4. Key Chinese CRO Players
4.1 Wuxi AppTec
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Investment and Development
4.1.6 Forecast and Outlook
4.2 Hangzhou Tigermed Consulting Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Forecast and Outlook
4.3 Guangzhou Boji Medical Biotechnological Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Forecast and Outlook
4.4 ShangPharma Corp
4.4.1 Profile
4.4.2 Operation
4.4.3 Gross Margin
4.5 China Medical Technologies Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 Development
4.6 Asymchem
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Forecast and Outlook
4.7 HD Biosciences
4.7.1 Profile
4.7.2 Operation
4.7.3 Development
4.8 Porton
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D and Investment
4.8.6 Forecast and Outlook
4.9 Others
4.9.1 Shanghai Mediclon Inc.
4.9.2 Sundia MediTech Company Ltd.
4.9.3 Guangzhou Yushi Medicinal Technology Co., Ltd.
4.9.4 JOINN Laboratories (Beijing) 

5. Key Foreign CRO Companies
5.1 Covance
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 Development in China
5.2 Parexel
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Development in China
5.3 Quintiles
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Development in China
5.4 Charles River
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Development in China
5.5 PPD
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Development in China

6. Development and Outlook
6.1 Industry Development Prediction
6.2 Operation of Major CRO Companies
6.2.1 Revenue
6.2.2 Net Income
6.2.3 Gross Margin
Classification of Pharmaceutical Outsourcing
R&D Process of New Drugs
Research Application of New Drugs in China, 2010-2014
China’s Policies on CRO Industry, 2001-2015 
Market Size and YoY Growth of China’s CRO Industry, 2007-2014 
Layout of Major Global CRO Companies in Asia
Distribution of Major Foreign CRO Companies in China
Business Mode of Chinese CRO Companies 
Market Share of China’s CRO Industry by Company, 2014 
R&D Costs of International Pharmaceutical Giants, 2009-2014 
Sales of Global Top 10 Pharmaceutical Companies, 2014
Market Size and YoY Growth of Global CRO Industry, 2007-2014 
Market Share of Global CRO Industry by Region, 2014 
Revenue and Total Profit of Chinese Pharmaceutical Enterprises, 2010-2014
Revenue of Chinese Pharmaceutical Enterprises by Province, 2014
Major Regions and Characteristics of China’s Pharmaceutical Industry, 
Capital Transactions and Disclosed Amount of Biomedical Industry in Beijing, 2014
Revenue and YoY Growth of Enterprises under ABO Alliance, 2007-2014 
Initiators of Zhongguancun CRO Alliance (Listed Randomly)
Platform Advantages of Zhangjiang Drug Valley
List of Major CRO Companies in Zhangjiang Drug Valley
Business Areas Distribution of WuXi AppTec
WuXi AppTec’s Revenue and Net Income, 2010-2015 
WuXi AppTec’s Revenue Breakdown by Business, 2010-2015 
WuXi AppTec’s Revenue Structure by Business, 2010-2015 
WuXi AppTec’s Revenue Breakdown by Region, 2010-2014 
WuXi AppTec’s Revenue Structure by Region, 2010-2014 
WuXi AppTec’s Gross Margin, 2010-2015 
WuXi AppTec’s Gross Margin by Business, 2010-2015 
WuXi AppTec’s Revenue and Net Income, 2013-2018E
Revenue and Net Income of Tigermed Consulting, 2010-2015 
Tigermed Consulting’s Revenue Breakdown by Business, 2013-2014
Tigermed Consulting’s Revenue Structure by Business, 2013-2014 
Tigermed Consulting’s Revenue Breakdown by Region, 2010-2014 
Tigermed Consulting’s Revenue Structure by Region, 2010-2014 
Tigermed Consulting’s Gross Margin, 2010-2015 
Tigermed Consulting’s Gross Margin by Region, 2010-2014
Tigermed Consulting’s R&D Costs and % of Total Revenue, 2011-2014 
Tigermed Consulting’s Revenue and Net Income, 2014-2018E
Boji Medical Biotechnological’s Revenue and Net Income, 2011-2015 
Boji Medical Biotechnological’s Revenue Breakdown by Business, 2011-2014 
Boji Medical Biotechnological’s Revenue Structure by Business, 2011-2014 
Boji Medical Biotechnological’s Revenue Breakdown by Region, 2011-2014 
Boji Medical Biotechnological’s Gross Margin, 2011-2015 
Boji Medical Biotechnological’s Gross Margin by Business, 2011-2014 
R&D Costs and % of Total Revenue of Boji Medical Biotechnological, 2011-2014 
Major Service Content of Boji Medical Biotechnological
Boji Medical Biotechnological’s Subsidiaries and Their Main Business
Fundraising Projects of Boji Medical Biotechnological
Revenue and Net Income of Boji Medical Biotechnological, 2014-2018E
ShangPharma Corp’s Organization Structure
ShangPharma Corp’s Revenue and Net Income, 2009-2014 
ShangPharma Corp’s Gross Margin, 2009-2014 
Revenue and Net Income of China Medical Technologies, 2010-2015 
Gross Margin of China Medical Technologies, 2010-2015 
Asymchem’s Revenue and Net Income, 2011-2014 
Asymchem’s Revenue Breakdown by Business, 2011-2014 
Asymchem’s Revenue Structure by Business, 2011-2014 
Asymchem’s Gross Margin, 2011-2014 
Asymchem’s R&D Costs and % of Total Revenue, 2011-2013 
Asymchem’s Major Subsidiaries and Offices
Asymchem’s Orders by Type, 2011-2013 
Asymchem’s Proposed Fundraising Project through IPO, May 2014
Asymchem’s Revenue and Net Income, 2013-2018E
HD Biosciences’ Revenue and Net Income, 2013-2014 
HD Biosciences’ Total Assets and Liabilities, 2013-2014 
Porton’s Revenue and Net Income, 2010-2015 
Porton’s Revenue Breakdown by Region, 2010-2015 
Porton’s Revenue Structure by Region, 2010-2014 
Porton’s Gross Margin, 2010-2015 
Porton’s Gross Margin by Region, 2010-2014 
Porton’s R&D Costs and % of Total Revenue, 2012-2014 
Porton’s Fundraising Project
Porton’s Revenue and Net Income, 2014-2018E
Covance’s Revenue and Net Income, 2009-2014 
Covance’s Revenue Breakdown by Business, 2009-2014 
Covance’s Revenue Structure by Business, 2009-2014 
Covance’s Revenue Breakdown by Region, 2011-2014 
Covance’s Revenue Structure by Region, 2011-2014 
Covance’s Gross Margin, 2009-2014 
Parexel’s Revenue and Net Income, 2009-2014 
Parexel’s Revenue Breakdown by Business, 2009-2014 
Parexel’s Revenue Structure by Business, 2009-2014 
Parexel’s Revenue Breakdown by Region, 2009-2014 
Parexel’s Revenue Structure by Region, 2009-2014 
Quintiles’ Revenue and Net Income, 2010-2015 
Quintiles’ Revenue Breakdown by Business, 2010-2015 
Quintiles’ Revenue Structure by Business, 2010-2015 
Quintiles’ Revenue Breakdown by Region, 2010-2015 
Quintiles’ Revenue Structure by Region, 2010-2014 
Quintiles’ Gross Margin, 2010-2015 
Charles River’s Revenue and Net Income, 2010-2015 
Charles River’s Revenue Breakdown by Business, 2013-2015 
Charles River’s Revenue Structure by Business, 2013-2015 
Charles River’s Revenue Breakdown by Region, 2011-2014 
Charles River’s Revenue Structure by Region, 2011-2014 
Charles River’s Gross Margin, 2010-2015 
PPD’s Revenue and Net Income, 2008-2011 
PPD’s Revenue Breakdown by Business, 2008-2011 
PPD’s Revenue Structure by Business, 2008-2011 
Global Proprietary Drugs Having Expired or to Expire, 2014-2016 
Market Share and YoY Growth Rate of China’s CRO Industry, 2014-2018E
Revenue of Major Chinese CRO Companies, 2010-2014 
Net Income of Major Chinese CRO Companies, 2010-2014 
Net Profit Margin of Major Chinese CRO Companies, 2010-2014 
Gross Margin of Major Chinese CRO Companies, 2010-2014 

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号